Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albiglutide versus placebo in insulin-treated subjects with new-onset type 1 diabetes mellitus
2014-001825-33Phase 2Terminated
- Sponsor
- GSK
- Start
- Jul 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Albiglutide plus insulin with Placebo plus insulin (2 arms). Primary endpoint: Change in 2-hour plasma C-peptide AUC at Week 52. Started Jul 2014; status: terminated.
02
Drugs
albiglutide
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2014-001825-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001825-33.